Climb Bio, Inc.
CLYM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001768446
In the last 90 days, Climb Bio, Inc. insiders filed 0 open-market purchases and 1 sale; 108 institutions reported holding it in 13F filings for Q2 2026, worth $734.3M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Climb Bio, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 35 | 43 | +8 |
| Shares | 17.4M | 17.5M | +125.7K (+0.7%) |
| Value | $181.8M | $146.8M | −$35.0M (−19.3%) |
New holders (11)
Institutions that held Climb Bio, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Point72 Asset Management, L.P. | 142,333 | $1.19M | 0.01% |
| Silverarc Capital Management, LLC | 88,279 | $741.0K | 0.40% |
| Bridgeway Capital Management, LLC | 18,400 | $154.0K | 0.00% |
| Qube Research & Technologies Ltd | 15,874 | $133.0K | 0.00% |
| Stifel Financial Corp | 10,157 | $85.0K | 0.00% |
| Barclays PLC | 2,850 | $24.0K | 0.00% |
| Amalgamated Bank | 1,039 | $9.00K | 0.00% |
| Amalgamated Financial Corp. | 1,039 | $9.00K | 0.00% |
| Cubist Systematic Strategies, LLC | 638 | $5.00K | 0.00% |
| FMR LLC | 94 | $1.00K | 0.00% |
| Point72 Hong Kong Ltd | 170 | $1.00K | 0.00% |
Sold out (3)
Institutions that held Climb Bio, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Caas Capital Management LP | 75,000 | $785.0K |
| Parametric Portfolio Associates LLC | 47,191 | $494.0K |
| Old Well Partners, LLC | 10,300 | $108.0K |